Logo image of AKYA

AKOYA BIOSCIENCES INC (AKYA) Stock Fundamental Analysis

NASDAQ:AKYA - US00974H1041 - Common Stock

1.29 USD
-0.07 (-5.15%)
Last: 7/7/2025, 8:00:00 PM
1.2899 USD
0 (-0.01%)
After Hours: 7/7/2025, 8:00:00 PM
Fundamental Rating

1

AKYA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 54 industry peers in the Life Sciences Tools & Services industry. AKYA may be in some trouble as it scores bad on both profitability and health. AKYA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AKYA has reported negative net income.
In the past year AKYA has reported a negative cash flow from operations.
AKYA had negative earnings in each of the past 5 years.
In the past 5 years AKYA always reported negative operating cash flow.
AKYA Yearly Net Income VS EBIT VS OCF VS FCFAKYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -42.20%, AKYA is not doing good in the industry: 80.36% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -42.2%
ROE N/A
ROIC N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
AKYA Yearly ROA, ROE, ROICAKYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

With an excellent Gross Margin value of 61.74%, AKYA belongs to the best of the industry, outperforming 82.14% of the companies in the same industry.
In the last couple of years the Gross Margin of AKYA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for AKYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
AKYA Yearly Profit, Operating, Gross MarginsAKYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

0

2. Health

2.1 Basic Checks

AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKYA has more shares outstanding
The number of shares outstanding for AKYA has been increased compared to 5 years ago.
AKYA has a worse debt/assets ratio than last year.
AKYA Yearly Shares OutstandingAKYA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AKYA Yearly Total Debt VS Total AssetsAKYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

AKYA has an Altman-Z score of -4.23. This is a bad value and indicates that AKYA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.23, AKYA is doing worse than 89.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.23
ROIC/WACCN/A
WACC12.42%
AKYA Yearly LT Debt VS Equity VS FCFAKYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

AKYA has a Current Ratio of 0.61. This is a bad value and indicates that AKYA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.61, AKYA is not doing good in the industry: 98.21% of the companies in the same industry are doing better.
A Quick Ratio of 0.40 indicates that AKYA may have some problems paying its short term obligations.
The Quick ratio of AKYA (0.40) is worse than 96.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.4
AKYA Yearly Current Assets VS Current LiabilitesAKYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.69% over the past year.
The Revenue for AKYA has decreased by -14.55% in the past year. This is quite bad
AKYA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.10% yearly.
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-14.55%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%

3.2 Future

Based on estimates for the next years, AKYA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.11% on average per year.
AKYA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.53% yearly.
EPS Next Y38.62%
EPS Next 2Y23.96%
EPS Next 3Y14.9%
EPS Next 5Y11.11%
Revenue Next Year4.99%
Revenue Next 2Y8.28%
Revenue Next 3Y7.01%
Revenue Next 5Y7.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AKYA Yearly Revenue VS EstimatesAKYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
AKYA Yearly EPS VS EstimatesAKYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AKYA. In the last year negative earnings were reported.
Also next year AKYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKYA Price Earnings VS Forward Price EarningsAKYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKYA Per share dataAKYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as AKYA's earnings are expected to grow with 14.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.96%
EPS Next 3Y14.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AKYA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (7/7/2025, 8:00:00 PM)

After market: 1.2899 0 (-0.01%)

1.29

-0.07 (-5.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners34.48%
Inst Owner Change-0.25%
Ins Owners4.15%
Ins Owner Change-130.54%
Market Cap64.44M
Analysts50.91
Price Target1.45 (12.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.8%
Min EPS beat(2)-53.04%
Max EPS beat(2)-2.56%
EPS beat(4)1
Avg EPS beat(4)-13.87%
Min EPS beat(4)-53.04%
Max EPS beat(4)1.15%
EPS beat(8)3
Avg EPS beat(8)-8.79%
EPS beat(12)4
Avg EPS beat(12)-9.37%
EPS beat(16)5
Avg EPS beat(16)-10.77%
Revenue beat(2)0
Avg Revenue beat(2)-10.08%
Min Revenue beat(2)-18.23%
Max Revenue beat(2)-1.93%
Revenue beat(4)0
Avg Revenue beat(4)-12.79%
Min Revenue beat(4)-27.44%
Max Revenue beat(4)-1.93%
Revenue beat(8)3
Avg Revenue beat(8)-9.2%
Revenue beat(12)7
Avg Revenue beat(12)-5.07%
Revenue beat(16)10
Avg Revenue beat(16)-2.97%
PT rev (1m)-24.7%
PT rev (3m)-54.86%
EPS NQ rev (1m)6.19%
EPS NQ rev (3m)-5.47%
EPS NY rev (1m)8.52%
EPS NY rev (3m)-6.25%
Revenue NQ rev (1m)-0.75%
Revenue NQ rev (3m)-6.21%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-5.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS1.6
BVpS-0.12
TBVpS-0.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.74%
FCFM N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25%
Cap/Sales 2.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.4
Altman-Z -4.23
F-Score5
WACC12.42%
ROIC/WACCN/A
Cap/Depr(3y)58.71%
Cap/Depr(5y)73.75%
Cap/Sales(3y)5.54%
Cap/Sales(5y)6.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y38.62%
EPS Next 2Y23.96%
EPS Next 3Y14.9%
EPS Next 5Y11.11%
Revenue 1Y (TTM)-14.55%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%
Revenue Next Year4.99%
Revenue Next 2Y8.28%
Revenue Next 3Y7.01%
Revenue Next 5Y7.53%
EBIT growth 1Y35.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.58%
EBIT Next 3Y7.24%
EBIT Next 5Y9.43%
FCF growth 1Y48.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.89%
OCF growth 3YN/A
OCF growth 5YN/A